These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. LYTACs: An Emerging Tool for the Degradation of Non-Cytosolic Proteins. Ramadas B; Kumar Pain P; Manna D ChemMedChem; 2021 Oct; 16(19):2951-2953. PubMed ID: 34296796 [TBL] [Abstract][Full Text] [Related]
4. Conjugation with glucagon like peptide-1 enables targeted protein degradation. Zhu L; Zhou Y; Zhang B; Luo Y; Fang C; Yan X; Cai Y; Jiang L; Ge J Bioorg Chem; 2023 Dec; 141():106908. PubMed ID: 37827016 [TBL] [Abstract][Full Text] [Related]
5. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Ahn G; Banik SM; Miller CL; Riley NM; Cochran JR; Bertozzi CR Nat Chem Biol; 2021 Sep; 17(9):937-946. PubMed ID: 33767387 [TBL] [Abstract][Full Text] [Related]
6. Programming DNA Nanoassemblies into Polyvalent Lysosomal Degraders for Potent Degradation of Pathogenic Membrane Proteins. Yu S; Shi T; Li C; Xie C; Wang F; Liu X Nano Lett; 2024 Sep; 24(37):11573-11580. PubMed ID: 39225423 [TBL] [Abstract][Full Text] [Related]
7. Targeted degradation of membrane and extracellular proteins with LYTACs. Li YY; Yang Y; Zhang RS; Ge RX; Xie SB Acta Pharmacol Sin; 2024 Aug; ():. PubMed ID: 39103530 [TBL] [Abstract][Full Text] [Related]
8. Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins. Yu J; Li H; Fang T; Yun C; Liu X; Xu J; Jiang X; Cai X J Am Chem Soc; 2023 Aug; 145(34):19107-19119. PubMed ID: 37552887 [TBL] [Abstract][Full Text] [Related]
9. Expression, purification, and characterization of human mannose-6-phosphate receptor - Extra cellular domain from a stable cell line utilizing a small molecule biomimetic of the mannose-6-phosphate moiety. Dwyer B; Lundberg D; Iskenderian A; Strack-Logue B; Pescatore B; Norton AW; Xu J; Meiyappan M; Concino MF; Zhang B Protein Expr Purif; 2020 Jun; 170():105589. PubMed ID: 32027983 [TBL] [Abstract][Full Text] [Related]
10. Retromer has a selective function in cargo sorting via endosome transport carriers. Cui Y; Carosi JM; Yang Z; Ariotti N; Kerr MC; Parton RG; Sargeant TJ; Teasdale RD J Cell Biol; 2019 Feb; 218(2):615-631. PubMed ID: 30559172 [TBL] [Abstract][Full Text] [Related]
11. IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins. Mikitiuk M; Barczyński J; Bielski P; Arciniega M; Tyrcha U; Hec A; Lipińska AD; Rychłowski M; Holak TA; Sitar T Molecules; 2023 Nov; 28(22):. PubMed ID: 38005242 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor. Su LY; Tian Y; Zheng Q; Cao Y; Yao M; Wang S; Xu W; Xi C; Clocchiatti A; Nie G; Zhou H Cell Chem Biol; 2024 Jun; 31(6):1219-1230.e5. PubMed ID: 38309277 [TBL] [Abstract][Full Text] [Related]
13. Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins. Wu Y; Lin B; Lu Y; Li L; Deng K; Zhang S; Zhang H; Yang C; Zhu Z Angew Chem Int Ed Engl; 2023 Apr; 62(15):e202218106. PubMed ID: 36722696 [TBL] [Abstract][Full Text] [Related]
14. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745 [TBL] [Abstract][Full Text] [Related]
15. Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation. Calcagni' A; Staiano L; Zampelli N; Minopoli N; Herz NJ; Di Tullio G; Huynh T; Monfregola J; Esposito A; Cirillo C; Bajic A; Zahabiyon M; Curnock R; Polishchuk E; Parkitny L; Medina DL; Pastore N; Cullen PJ; Parenti G; De Matteis MA; Grumati P; Ballabio A Nat Commun; 2023 Jul; 14(1):3911. PubMed ID: 37400440 [TBL] [Abstract][Full Text] [Related]
16. A role of GCC88 in the retrograde transport of CI-M6PR and the maintenance of lysosomal activity. Cui Y; Yang Z; Teasdale RD Cell Biol Int; 2019 Nov; 43(11):1234-1244. PubMed ID: 30791178 [TBL] [Abstract][Full Text] [Related]
17. Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis. Zhou P; Zhang S; Li L; Zhang R; Guo G; Zhang Y; Wang R; Liu M; Wang Z; Zhao H; Yang G; Xie S; Ran J Theranostics; 2024; 14(13):4983-5000. PubMed ID: 39267779 [No Abstract] [Full Text] [Related]
18. Inhibition of insulin-like growth factor II (IGF-II)-dependent cell growth by multidentate pentamannosyl 6-phosphate-based ligands targeting the mannose 6-phosphate/IGF-II receptor. Zavorka ME; Connelly CM; Grosely R; MacDonald RG Oncotarget; 2016 Sep; 7(38):62386-62410. PubMed ID: 27694692 [TBL] [Abstract][Full Text] [Related]
19. Targeted Analysis of Lysosomal Directed Proteins and Their Sites of Mannose-6-phosphate Modification. Čaval T; Zhu J; Tian W; Remmelzwaal S; Yang Z; Clausen H; Heck AJR Mol Cell Proteomics; 2019 Jan; 18(1):16-27. PubMed ID: 30237200 [TBL] [Abstract][Full Text] [Related]
20. A Nucleic Acid-Based LYTAC Plus Platform to Simultaneously Mediate Disease-Driven Protein Downregulation. Huang Y; Zhou X; Zhang Y; Xie M; Wang F; Qin J; Ye H; Zhang H; Zhang C; Hong J Adv Sci (Weinh); 2024 Apr; 11(13):e2306248. PubMed ID: 38251411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]